Details

Autor(en) / Beteiligte

• Fujiwara, Mai
• Raheja, Radhika
• Garo, Lucien P
• Ajay, Amrendra K
• Kadowaki-Saga, Ryoko
• Karandikar, Sukrut H
• Gabriely, Galina
• Krishnan, Rajesh
• Beynon, Vanessa
• Paul, Anu
• Patel, Amee
• Saxena, Shrishti
• Hu, Dan
• Healy, Brian C
• Chitnis, Tanuja
• Gandhi, Roopali
• Weiner, Howard L
• Murugaiyan, Gopal

Titel

microRNA-92a promotes CNS autoimmunity by modulating the regulatory and inflammatory T cell balance

Ist Teil von

• The Journal of clinical investigation, 2022-05, Vol.132 (10), p.1-16

Ort / Verlag

United States: American Society for Clinical Investigation

Erscheinungsjahr

2022

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• A disequilibrium between immunosuppressive Tregs and inflammatory IL-17-producing Th17 cells is a hallmark of autoimmune diseases, including multiple sclerosis (MS). However, the molecular mechanisms underlying the Treg and Th17 imbalance in CNS autoimmunity remain largely unclear. Identifying the factors that drive this imbalance is of high clinical interest. Here, we report a major disease-promoting role for microRNA-92a (miR-92a) in CNS autoimmunity. miR-92a was elevated in experimental autoimmune encephalomyelitis (EAE), and its loss attenuated EAE. Mechanistically, miR-92a mediated EAE susceptibility in a T cell-intrinsic manner by restricting Treg induction and suppressive capacity, while supporting Th17 responses, by directly repressing the transcription factor Foxo1. Although miR-92a did not directly alter Th1 differentiation, it appeared to indirectly promote Th1 cells by inhibiting Treg responses. Correspondingly, miR-92a inhibitor therapy ameliorated EAE by concomitantly boosting Treg responses and dampening inflammatory T cell responses. Analogous to our findings in mice, miR-92a was elevated in CD4+ T cells from patients with MS, and miR-92a silencing in patients' T cells promoted Treg development but limited Th17 differentiation. Together, our results demonstrate that miR-92a drives CNS autoimmunity by sustaining the Treg/Th17 imbalance and implicate miR-92a as a potential therapeutic target for MS.